EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination

Victoria E Brown iD, Sydney L Moore, Maxine Chen, Nealia House iD, Philip Ramsden, Hsin-Jung Wu, Scott Ribich, Alexandra R Grassian, Yoon Jong Choi

NAR Cancer · 2023

DOI: 10.1093/narcan/zcad039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, 2023. Verfasst von Victoria E Brown und 8 weiteren Autor:innen. Beteiligte Einrichtung: Blueprint Medicines, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Cyclin E, Ovarian Neoplasms, Cyclin-Dependent Kinase 2, Homologous Recombination. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Blueprint Medicines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CCNE1 amplification is a common alteration in high-grade serous ovarian cancer and occurs in 15–20% of these tumors. These amplifications are mutually exclusive with homologous recombination deficiency, and, as they have intact homologous recombination, are intrinsically resistant to poly (ADP-ribose) polymerase inhibitors or chemotherapy agents. Understanding the molecular mechanisms that lead to this mutual exclusivity may reveal therapeutic vulnerabilities that could be leveraged in the clinic in this still underserved patient population. Here, we demonstrate that CCNE1-amplified high-grade serous ovarian cancer cells rely on homologous recombination to repair collapsed replication forks. Cyclin-dependent kinase 2, the canonical partner of cyclin E1, uniquely regulates homologous recombination in this genetic context, and as such cyclin-dependent kinase 2 inhibition synergizes with DNA damaging agents in vitro and in vivo. We demonstrate that combining a selective cyclin-dependent kinase 2 inhibitor with a DNA damaging agent could be a powerful tool in the clinic for high-grade serous ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin EOvarian NeoplasmsCyclin-Dependent Kinase 2Homologous RecombinationOncogene ProteinsDNA ReplicationDNA RepairCystadenocarcinoma, SerousFemaleHumansCell Line, TumorAnimalsMiceDNA DamageGene AmplificationXenograft Model Antitumor Assays

Substanzen

Cyclin ECCNE1 protein, humanCyclin-Dependent Kinase 2Oncogene ProteinsCDK2 protein, human

Autor:innen und Institutionen

  • Blueprint Medicines, Cambridge, MA 02139, USA.
  • Department of Biology, Tufts University, Medford, MA 02155, USA.

ORCID-Profile: Victoria E Brown, Nealia House

Förderung

  • Blueprint Medicines

Zitieren

APA

Brown, V. E., Moore, S. L., Chen, M., House, N., Ramsden, P., Wu, H. J., Ribich, S., Grassian, A. R., & Choi, Y. J. (2023). CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination. NAR Cancer. https://doi.org/10.1093/narcan/zcad039

Vancouver

Brown VE, Moore SL, Chen M, House N, Ramsden P, Wu HJ, et al. CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination. NAR Cancer. 2023. doi:10.1093/narcan/zcad039

BibTeX
@article{Brown2023,
  author = {Brown, Victoria E and Moore, Sydney L and Chen, Maxine and House, Nealia and Ramsden, Philip and Wu, Hsin-Jung and Ribich, Scott and Grassian, Alexandra R and Choi, Yoon Jong},
  title = {CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination},
  journal = {NAR Cancer},
  year = {2023},
  doi = {10.1093/narcan/zcad039}
}
Kostenlos starten →